CLAIMS

1. Use of a pharmaceutical composition, wherein said pharmaceutical composition reduces the expression of ~~one or more genes selected from CXCL13, SPP1,~~ MMP12 and MMP13, in the manufacture of a medicament for the treatment of acne vulgaris ~~a skin disorder~~ in a subject in need thereof, ~~and~~ wherein the pharmaceutical composition comprises from 1 µg/g to 100 µg /g of a pharmaceutical agent, and wherein the said medicament is to be administered.

~~2. Use of a pharmaceutical composition that reduces the expression of CXCL13, in the manufacture of a medicament for the treatment of a skin disorder in a subject, wherein said medicament is to be administered.~~

~~3. Use of a pharmaceutical composition that reduces the expression of MMP12 and/or MMP13, in the manufacture of a medicament for the treatment of a skin disorder in a subject, wherein said medicament is to be administered.~~

~~4. Use of a pharmaceutical composition that reduces the expression of SPP1, in the manufacture of a medicament for the treatment of a skin disorder in a subject, wherein said medicament is to be administered.~~

~~5~~2. The use according to any of the preceding claims, wherein the pharmaceutical composition comprises a therapeutically effective amount of a pharmaceutical agent and a pharmaceutically acceptable carrier.

~~6. The use according to any of the preceding claims, wherein the pharmaceutical composition comprises from about 1 µg/g to about 100 µg/g of a pharmaceutical agent.~~

~~7~~3. The use according to according to claim ~~5 or claim 6~~2, wherein the pharmaceutical composition is administered once daily, twice daily, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

~~8~~4. The use according to any of the preceding claims, wherein the pharmaceutical composition is formulated as a cream or as an oil-in-water emulsion.

~~9. The use according to any of the preceding claims, wherein the skin disorder is acne vulgaris.~~

~~10~~5. The use according to any of the preceding claims, wherein the acne vulgaris ~~skin disorder~~ is acne vulgaris of the face or trunk.

~~11~~6. The use according to any of the preceding claims, wherein the acne vulgaris comprises mild, moderate and severe acne vulgaris.

~~12~~7. The use according to any of the preceding claims, wherein the pharmaceutical composition is to be topically administered to the area of the subject affected with acne vulgaris.

~~13~~8. Use of a pharmaceutical composition that reduces the expression of ~~one or more genes selected from CXCL13, SPP1,~~ MMP12 and MMP13, in the manufacture of a medicament for modulating an adaptive immune response in a subject to effect a treatment of acne vulgaris~~a skin disorder~~, wherein said medicament is to be administered.

~~14~~9. Use of a pharmaceutical composition that reduces the expression of ~~one or more genes selected from CXCL13, SPP1,~~ MMP12 and MMP13, in the manufacture of a medicament for alleviating inflammatory response associated with acne vulgaris ~~skin disorders~~ in a subject, wherein said medicament is to be administered.

~~15. The use of claim 14, wherein the skin disorder is acne vulgaris and the method comprises treating acne vulgaris.~~

~~16~~11. The use of claim ~~14~~9, wherein the ~~method~~ use decreases inflammation in the skin of the subject.

~~17. Use of a therapeutically effective amount of a pharmaceutical agent which reduces the expression of CXCL13, in the manufacture of a medicament for antagonizing CXCR5 receptor activity in a patient suffering from acne vulgaris, wherein said medicament is to be administered.~~

~~18. A method of monitoring or determining efficacy of an acne treatment in a subject, the method comprising determining in a sample from said subject the expression of one or more genes selected from CXCL13, SPP1, MMP12 and MMP13.~~

~~19. The method of claim 18, wherein the subject prior to the monitoring, has already been treated with a pharmaceutical composition that reduces the expression of one or more genes selected from CXCL13, SPP1, MMP12 and MMP13.~~

~~20. The method of claim 18, wherein a decrease or an increase in the expression of one or more genes selected from CXCL13, SPP1, MMP12 and MMP13 in the sample relative to the controls is used to determine the efficacy of the acne treatment.~~

12. The method of claim 1, wherein the pharmaceutical agent comprises trifarotene or an equivalent thereof.